search
Back to results

Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival

Primary Purpose

Cardiac Arrest

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Morphine
Ketamine Injectable Solution
Saline 0.9%
Sponsored by
University Hospital, Akershus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiac Arrest focused on measuring cardiac arrest, Morphine, Ketamine, Survival rate

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- All adult patients with in-hospital cardiac arrest

Exclusion Criteria:

  • an age of less than 18 years
  • drugs poisoning or the administration of opioids or Ketamine 24 hours before the cardiac arrest
  • terminal phase of oncological or other chronic diseases
  • poor communication and physical capabilities due to psychiatric or neurological diseases
  • dementia or Alzheimers
  • extremely reduced weight or physical ability and activity
  • known history of chronic use of opioids/Ketamine

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    Morphine

    Ketamine

    Saline

    Arm Description

    Morphine group (M) (n=80), where patients will be treated with i.v. injection of Morphine 2 mg/ml - 5 ml - 10 mg "Epidural". The treatment will be given during CPR as soon as possible.

    Ketamine (K) group (n=80), where patients will be treated with i.v. injection of S-Ketamine 10 mg/ml - 5 ml - 50 mg "Ketamin Abcur". The treatment will be given during CPR as soon as possible.

    Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% "B. Braun". The treatment will be given during CPR as soon as possible.

    Outcomes

    Primary Outcome Measures

    Survival at 28 days in patients after in-hospital cardiac arrest
    Survival rate at 28 days in patients after in-hospital cardiac arrest treated or not with Morphine or ketamine during CPR

    Secondary Outcome Measures

    Measurement of biochemical markers of brain damage (NSE, S-100B protein)
    Measurement of biochemical markers of brain damage (NSE, S-100B protein) at 2,12, 24 and 48 hours in patients after out-of-hospital cardiac arrest.
    Length of stay in the intensive care unit
    Registration of length of patients stay (days) in the intensive care units
    Length of stay in the hospital
    Registration of patients stay (days) in the hospitals
    Survival rate at 3 months after cardiac arrest
    Registration of survival rate at 3 months after cardiac arrest
    Neurological outcome at the hospital discharge
    Modified Rankin Scale (mRS) will be used for evaluation of neurological outcome. The mRS-9Q Survey and web calculator / error-checker can be accessed freely at: www.modifiedrankin.com. The mRS score encodes meaningful levels of function from no symptoms or functional impairment (mRS score = 0) through to severe disability requiring constant nursing care (mRS score = 5). the mRS-9Q is an easy-to-use tool to determine the mRS score with very good interobserver reliability and reproducibility. Web-based calculator can be also administered by personnel without clinical training, either in person or by telephone.
    neurological outcome at 3 months after cardiac arrest
    Modified Rankin Scale (mRS) will be used for evaluation of neurological outcome. The mRS-9Q Survey and web calculator / error-checker can be accessed freely at: www.modifiedrankin.com. The mRS score encodes meaningful levels of function from no symptoms or functional impairment (mRS score = 0) through to severe disability requiring constant nursing care (mRS score = 5). the mRS-9Q is an easy-to-use tool to determine the mRS score with very good interobserver reliability and reproducibility. Web-based calculator can be also administered by personnel without clinical training, either in person or by telephone.

    Full Information

    First Posted
    February 16, 2019
    Last Updated
    June 8, 2021
    Sponsor
    University Hospital, Akershus
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04009759
    Brief Title
    Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival
    Official Title
    Randomized Triple-blind Placebo Controlled Trial of Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival and Neurological Outcome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2021
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2021 (Anticipated)
    Primary Completion Date
    January 1, 2025 (Anticipated)
    Study Completion Date
    January 1, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University Hospital, Akershus

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    A small numbers of patients (10-15%) treated with cardiopulmonary resuscitation (CPR) are discharged from hospitals with a favorable neurologic outcome. However, a higher incidence of chest injuries (30-70%), mainly rib and sternum fractures, are observed among the survivors. It's no surprise that 6 months after cardiac arrest (CA) 50-70% of the patients who have survived continue to have pain and stress-related problems. Based on the need for the pain/stress treatment in these patients and several experimental evidences demonstrating neuroprotective features of anesthetics it is logical to presume that application of anesthesia during CPR may be indicated. In rodents exposed to hypoxic gas (5% 02, 95% N2) for 70 min, all seven animals died at the end of the experiments in the naloxone pre-treated group while only one out of seven rats died in the morphine pre-treated group, and five of seven rats died in the control group. In human volunteers, intravenously administered 60 mg of morphine did not alter cerebral blood flow and cerebral vascular resistance but markedly depressed cerebral oxygen uptake. Interestingly, in critical patients, morphine even in low doses is effective in relieving dyspnea by altering central perception and decreasing anxiety. In rats, morphine demonstrates dose- depending reduction of cerebral glucose utilization in limbic and forebrain regions. Thus, the main points of application for morphine in treatment of CA may be a reduction of oxygen/glucose consumption. Pre-treatment of zebrafish with ketamine protects against cardiac arrest-induced brain injury by inhibiting Ca2+ wave propagation and consequently it improves survival rate. Inhibition of NMDA receptors by ketamine reduces neuronal apoptosis and attenuates the systemic inflammatory response to tissue injury. The sympathomimetic effects of ketamine may facilitates recovery of systemic blood pressure during CPR. Retrospective investigations demonstrate that patients who are treated with opioids before or during CA have a statistically significantly higher survival rate and much better neurological outcome compared to untreated patients. Experimental studies have a limitation as all animals are treated with anesthesia and therefore survival rate varies between 50-90%. Thus, prospective research is urgently needed to investigate the influence of morphine or/and ketamine on survival and neurological outcome in patients with CA.
    Detailed Description
    Almost 35 years ago, Dr Peter Safar wrote that "cerebral recovery from more than 5 min of cardiac arrest is hampered by complex secondary derangements of multiple organ systems after reperfusion". Actually, these 5 "golden" minutes determine the ability of cerebral neurones to regain ordinary function after anoxia. The ordinary function of cerebral neurones is conduction of electrical impulses across their length from the post-synaptic membrane of dendrites to the presynaptic membrane of an axon. The process is based on exchange of Ca2+, Na+ and K+ between the extra- and intracellular space of cerebral neurones, and therefore a lot of energy in the form of adenosine triphosphate (ATP) is needed to remove Ca2+ and Na+ from the intracellular space of these cells. Cardiac arrest (CA) initiates a switch to glycolytic metabolism with very low production of ATP and the increased levels of lactate and H+. Both acidosis and the lack of ATP inhibit the ions pumps, which are responsible for handling excessive intracellular accumulation of Ca2+ and Na+. Preclinical studies demonstrate that acute hypoxia results in an uncontrolled release of glutamate with consequent stimulation of the N-methyl-D-aspartate (NMDA) receptors causing also an excessive Ca2+ influx. Meanwhile, the ATP reservoir in neurones can be completely depleted after 5 minutes of no-flow state. In case of oxygen supplying restoration, two molecules of ATP are initially required to split glucose and restart the cellular respiration. Thus, the presence or absence of these two molecules of ATP in neurones actually determine restoring of both oxidative phosphorylation and the ordinary function of the neurones. Finally, prolonged intracellular Ca2+ overload results in increased mitochondrial permeability causing following release of cytochrome C from mitochondria, and consequent cleavage and activation of caspase-3. Caspase-3 is an essential protease, which is involved in the early stage of apoptosis and it is generally accepted as a hallmark of irreversible cell death. Interestingly, in an experimental study with rats, the activation of caspase-3 was observed in a significant number of neurones of the cerebellum and neocortex only after 9 hours following asphyxial cardiac arrest. Today, only therapeutic hypothermia has been shown to have a beneficial impact on the ion pump dysfunction, and thereby reduce neurotoxicity. Interestingly, in hibernators, hypothermia is also believed to protect against hypoxic brain damage. Meanwhile, if naloxone, a non selective opioid receptor antagonist, is injected during the maintenance phase of hibernation, arousal is quickly achieved and the protective effects are vanished. Delta opioid peptides, previously discovered to induce hibernation have also been shown to protect rats from hypoxic brain damage. Based on the ability of opioids to reduce the level of cyclic adenosine monophosphate (cAMP), and consequently to block Na+ channels, it would be logical to propose that opioids might prevent the disturbance of ionic homeostasis during acute hypoxia. Indeed, preclinical studies demonstrate that opioids can preserve cellular integrity status during acute hypoxia in many organs and tissues including: intestine, skeletal muscle, myocardium and brain. Moreover, Morphine has been shown to significantly increase the survival of mice and rats in acute hypoxia conditions. In the experimental model with rats exposed to hypoxic gas (5% oxygen, 95% N2) for 70 min, all seven rats in the naloxone pre-treated group died at the end of the experiments while only one out of seven rats died in the Morphine (5 mg/kg) pretreated group, and five from the seven rats died in the control group. In the experiments where the rats were exposed to 8 min anoxia, pre-treatment with Morphine (5mg/kg), or Ketamine (40 mg/kg), resulted in higher survival in both groups as compared to the control group (data not yet published). No publications looking at the survival rate in animals with treatment by Morphine before cardiac arrest have been published yet. Meanwhile, two recent retrospective studies demonstrated that patients who were treated with opioids before or during cardiac arrest had a statistically significantly higher survival rate and much better neurological outcome compared to untreated patients. Recently published data shows that the Na+ influx initiating the action potential in neurones consumes one third the ATP of synaptic potentials associated with Ca2+ influx. In theory, Ketamine that inhibits the synaptic potentials by NMDA receptor blockade, might save much more ATP in the neurones compared to Morphine, which inhibits only Na+ influx and accordingly the action potentials. Certainly, after restoration of blood flow, the residual saved ATP may contribute to restoration of both neuronal oxidative phosphorylation and ionic exchange. Newly published experimental data demonstrates that pre-treatment of zebrafish with Ketamine protects against cardiac arrest induced brain injury by inhibiting Ca2+ wave propagation, which consequently improves survival rate. Contrary to the results seen in these studies, two NMDA antagonist, MK-801 and GPI-3000 in high doses did not improve survival rate and brain outcome after cardiac arrest and resuscitation in a dog model. These studies did not suggest any mechanisms of the negative results, but they contributed to a lack of interest for testing NMDA blockade in CA for years. More recently, a study of the effects of using the noncompetitive NMDA antagonist Ifenprodil demonstrated a significant reduction of brain oedema following asphyxial cardiac arrest in rats. In this study, i.v. injection of Ifenprodil also resulted in much more stable hemodynamic status after CA as compared with salt treated animals. Another experimental study of different anaesthesia regimes in a rodent cardiac arrest model also demonstrated much better hemodynamic status in the early post resuscitation period in the rats treated with Ketamine and Medetomidine as compared to anaesthesia with Sevoflurane and Fentanyl. All anaesthetics, with their ability to antagonise glutamate mediated excitotoxicity and inflammation might be logical candidates for neuroprotective treatment during cardiac arrest. However, the ability of anaesthetics to produce vasodilatation with a significant reduction of blood perfusing pressure can be the main argument against the idea to test their effects during cardio pulmonary resuscitation (CPR) in human. However, due to their minimal influences on hemodynamic status in therapeutic doses, Ketamine as well as Morphine can be considered as the safe candidates during neuroprotective treatment trials in CPR patients. Another argument for possible application of Morphine or Ketamine during CPR could be as an analgesic. Vigorous thoracic compression with possible trauma of the ribs may lead to severe pain and stress reactions in patients surviving CPR. The rationale for analysing plasma levels of S-100B protein and NSE in this trial will be their different distribution within the white (S100B protein) and grey (NSE) matter of the brain, and the fact that both of them are extensively involved in the pathogenesis of anoxial brain damage. S100 B protein is an intracellular calcium-binding dimer that has a molecular weight of 21 kDa and two hours of half life. Thanks to the low molecular weight, S100 B protein easily cross the blood-brain barrier and rapidly end up in the systemic circulation. NSE is a neuronal isoform of the glycolytic enzyme enolase that has a molecular weight of 78 kDa and a twenty four hours half life. Further, NSE is extensively involved in glucose metabolism in the neurones and can be detected only in neuronal and neuroendocrine tissues. Due to this organ specificity, concentration of NSE in blood is often elevated as a result of relative rapid and massive neuronal destruction. In clinical practice, elevated serum NSE levels, above 30 ng/ml, correlate well with a poor outcome in coma, particularly when caused by an hypoxic insult. Thus, these two markers of early neuronal damage is a good fit for testing the neuroprotective features of Morphine or Ketamine application during CPR. A retrospective evaluation of patients after cardiac arrest in the University hospital of Northern Norway demonstrated significantly higher 1, 2, 3 and 28 days survival rate and reduced duration of CPR in the patients additionally treated with opioids compared to ordinary resuscitation. Two years later another retrospective, observational cohort study from Pittsburgh, USA reported that despite poor baseline prognostic factors, survival after recreational drug overdose-related cardiac arrests (CA) was no worse than after non overdose-related arrest, and among survivors the majority had a good neurological outcome. Interestingly, the same research group reported in one previous retrospective study a higher rate of survival to hospital discharge (19% vs. 12%, p = 0.014) in the overdose CA group compared to the non-overdoses one. However, patients in these overdose cases were significantly younger (45 vs. 65, p < 0.001), but less likely to be witnessed by a bystander (29% vs. 41%, p < 0.005). Suspected overdose cases had a higher overall chest compression fraction (0.69 vs. 0.67, p = 0.018) and higher probability of adrenaline, sodium bicarbonate, and atropine administration (p < 0.001). Application of Naloxone in these overdose cases might have had an influence on survival as well. One previously published clinical case described full neurological recovery in a young man who overdosed on opioids and who regained sinus rhythm many minutes after resuscitation had been abandoned. Based on all of the above, it can be hypothesised that treatment with Morphine or Ketamine might have a beneficial impact on the conservation of ATP in the brain, and thereby the treatment might increase the ability of cerebral neurones to survive and regain ordinary function after CPR.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardiac Arrest
    Keywords
    cardiac arrest, Morphine, Ketamine, Survival rate

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Model Description
    240 adult patients with an in-hospital cardiac arrest will be evaluated by anesthesiologist on duty for inclusions criteria to the study and randomized to get the blinded study medicine as addition to the standard treatment of cardiac arrest.
    Masking
    Outcomes Assessor
    Masking Description
    Acute bag for cardiopulmonary resuscitation (CPR) will have a trial pack containing 3 blinded ampules that will be labelled with only randomisation number. Anaesthesiologists and nurses performing CPR and research treatment will not know the content of the ampules as well as a meaning of the randomisation number. Neurologist, who will not be aware of treatment assignments, will assess neurological outcomes in all survived patients. Statistician, who will not be aware of treatment assignments, will assess statistical data in all included patients. An independent Data Monitoring Committee will assess the progress, safety data (death, long-term hospitalization, and disability) and, critical efficacy endpoints of the clinical study (survival at 1, 2, 3 and 28 days in patients after in-hospital CA) in all included patients.
    Allocation
    Randomized
    Enrollment
    240 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Morphine
    Arm Type
    Active Comparator
    Arm Description
    Morphine group (M) (n=80), where patients will be treated with i.v. injection of Morphine 2 mg/ml - 5 ml - 10 mg "Epidural". The treatment will be given during CPR as soon as possible.
    Arm Title
    Ketamine
    Arm Type
    Active Comparator
    Arm Description
    Ketamine (K) group (n=80), where patients will be treated with i.v. injection of S-Ketamine 10 mg/ml - 5 ml - 50 mg "Ketamin Abcur". The treatment will be given during CPR as soon as possible.
    Arm Title
    Saline
    Arm Type
    Placebo Comparator
    Arm Description
    Control group (n=80), where patients will be treated with i.v. 5 ml of NaCl 0,9% "B. Braun". The treatment will be given during CPR as soon as possible.
    Intervention Type
    Drug
    Intervention Name(s)
    Morphine
    Intervention Description
    Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
    Intervention Type
    Drug
    Intervention Name(s)
    Ketamine Injectable Solution
    Other Intervention Name(s)
    Ketamine
    Intervention Description
    Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
    Intervention Type
    Drug
    Intervention Name(s)
    Saline 0.9%
    Other Intervention Name(s)
    Saline
    Intervention Description
    Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
    Primary Outcome Measure Information:
    Title
    Survival at 28 days in patients after in-hospital cardiac arrest
    Description
    Survival rate at 28 days in patients after in-hospital cardiac arrest treated or not with Morphine or ketamine during CPR
    Time Frame
    28th day
    Secondary Outcome Measure Information:
    Title
    Measurement of biochemical markers of brain damage (NSE, S-100B protein)
    Description
    Measurement of biochemical markers of brain damage (NSE, S-100B protein) at 2,12, 24 and 48 hours in patients after out-of-hospital cardiac arrest.
    Time Frame
    2,12, 24 and 48 hours
    Title
    Length of stay in the intensive care unit
    Description
    Registration of length of patients stay (days) in the intensive care units
    Time Frame
    3 month
    Title
    Length of stay in the hospital
    Description
    Registration of patients stay (days) in the hospitals
    Time Frame
    3 months
    Title
    Survival rate at 3 months after cardiac arrest
    Description
    Registration of survival rate at 3 months after cardiac arrest
    Time Frame
    3 months
    Title
    Neurological outcome at the hospital discharge
    Description
    Modified Rankin Scale (mRS) will be used for evaluation of neurological outcome. The mRS-9Q Survey and web calculator / error-checker can be accessed freely at: www.modifiedrankin.com. The mRS score encodes meaningful levels of function from no symptoms or functional impairment (mRS score = 0) through to severe disability requiring constant nursing care (mRS score = 5). the mRS-9Q is an easy-to-use tool to determine the mRS score with very good interobserver reliability and reproducibility. Web-based calculator can be also administered by personnel without clinical training, either in person or by telephone.
    Time Frame
    6 months
    Title
    neurological outcome at 3 months after cardiac arrest
    Description
    Modified Rankin Scale (mRS) will be used for evaluation of neurological outcome. The mRS-9Q Survey and web calculator / error-checker can be accessed freely at: www.modifiedrankin.com. The mRS score encodes meaningful levels of function from no symptoms or functional impairment (mRS score = 0) through to severe disability requiring constant nursing care (mRS score = 5). the mRS-9Q is an easy-to-use tool to determine the mRS score with very good interobserver reliability and reproducibility. Web-based calculator can be also administered by personnel without clinical training, either in person or by telephone.
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: - All adult patients with in-hospital cardiac arrest Exclusion Criteria: an age of less than 18 years drugs poisoning or the administration of opioids or Ketamine 24 hours before the cardiac arrest terminal phase of oncological or other chronic diseases poor communication and physical capabilities due to psychiatric or neurological diseases dementia or Alzheimers extremely reduced weight or physical ability and activity known history of chronic use of opioids/Ketamine
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Vladimir Kuklin, dr med
    Phone
    +4798838024
    Email
    vkuklin@me.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Lisa Dybvik, cand med
    Phone
    +4746669271
    Email
    ldybvik@hotmail.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    3536160
    Citation
    Safar P. Cerebral resuscitation after cardiac arrest: a review. Circulation. 1986 Dec;74(6 Pt 2):IV138-53.
    Results Reference
    background
    PubMed Identifier
    26567101
    Citation
    Schmitt KR, Tong G, Berger F. Mechanisms of hypothermia-induced cell protection in the brain. Mol Cell Pediatr. 2014 Dec;1(1):7. doi: 10.1186/s40348-014-0007-x. Epub 2014 Dec 1.
    Results Reference
    background
    PubMed Identifier
    2576507
    Citation
    Siesjo BK, Bengtsson F, Grampp W, Theander S. Calcium, excitotoxins, and neuronal death in the brain. Ann N Y Acad Sci. 1989;568:234-51. doi: 10.1111/j.1749-6632.1989.tb12513.x. No abstract available.
    Results Reference
    background
    PubMed Identifier
    2890549
    Citation
    Robinson MB, Coyle JT. Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB J. 1987 Dec;1(6):446-55. doi: 10.1096/fasebj.1.6.2890549.
    Results Reference
    background
    PubMed Identifier
    6139418
    Citation
    Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem. 1984 Jan;42(1):1-11. doi: 10.1111/j.1471-4159.1984.tb09689.x. No abstract available.
    Results Reference
    background
    PubMed Identifier
    2908446
    Citation
    Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988 Oct;1(8):623-34. doi: 10.1016/0896-6273(88)90162-6. No abstract available.
    Results Reference
    background
    PubMed Identifier
    1980041
    Citation
    Nicholls D, Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol Sci. 1990 Nov;11(11):462-8. doi: 10.1016/0165-6147(90)90129-v.
    Results Reference
    background
    PubMed Identifier
    8325535
    Citation
    Bondy SC, LeBel CP. The relationship between excitotoxicity and oxidative stress in the central nervous system. Free Radic Biol Med. 1993 Jun;14(6):633-42. doi: 10.1016/0891-5849(93)90144-j.
    Results Reference
    background
    PubMed Identifier
    18193649
    Citation
    Bernardi P, Rasola A. Calcium and cell death: the mitochondrial connection. Subcell Biochem. 2007;45:481-506. doi: 10.1007/978-1-4020-6191-2_18.
    Results Reference
    background
    PubMed Identifier
    10872455
    Citation
    Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424. doi: 10.1146/annurev.biochem.68.1.383.
    Results Reference
    background
    PubMed Identifier
    18784829
    Citation
    Sheleg SV, Lobello JR, Hixon H, Coons SW, Lowry D, Nedzved MK. Stability and autolysis of cortical neurons in post-mortem adult rat brains. Int J Clin Exp Pathol. 2008 Jan 1;1(3):291-9.
    Results Reference
    background
    PubMed Identifier
    24795283
    Citation
    Calderon LM, Guyette FX, Doshi AA, Callaway CW, Rittenberger JC; Post Cardiac Arrest Service. Combining NSE and S100B with clinical examination findings to predict survival after resuscitation from cardiac arrest. Resuscitation. 2014 Aug;85(8):1025-9. doi: 10.1016/j.resuscitation.2014.04.020. Epub 2014 Apr 30.
    Results Reference
    background
    PubMed Identifier
    23085028
    Citation
    Phillips KF, Deshpande LS, DeLorenzo RJ. Hypothermia reduces calcium entry via the N-methyl-D-aspartate and ryanodine receptors in cultured hippocampal neurons. Eur J Pharmacol. 2013 Jan 5;698(1-3):186-92. doi: 10.1016/j.ejphar.2012.10.010. Epub 2012 Oct 17.
    Results Reference
    background
    PubMed Identifier
    22381895
    Citation
    Tamura Y, Shintani M, Inoue H, Monden M, Shiomi H. Regulatory mechanism of body temperature in the central nervous system during the maintenance phase of hibernation in Syrian hamsters: involvement of beta-endorphin. Brain Res. 2012 Apr 11;1448:63-70. doi: 10.1016/j.brainres.2012.02.004. Epub 2012 Feb 9.
    Results Reference
    background
    PubMed Identifier
    19534760
    Citation
    Borlongan CV, Hayashi T, Oeltgen PR, Su TP, Wang Y. Hibernation-like state induced by an opioid peptide protects against experimental stroke. BMC Biol. 2009 Jun 17;7:31. doi: 10.1186/1741-7007-7-31.
    Results Reference
    background
    PubMed Identifier
    11212864
    Citation
    Zhang Y, Wu YX, Hao YB, Dun Y, Yang SP. Role of endogenous opioid peptides in protection of ischemic preconditioning in rat small intestine. Life Sci. 2001 Jan 19;68(9):1013-9. doi: 10.1016/s0024-3205(00)01004-3.
    Results Reference
    background
    PubMed Identifier
    12791590
    Citation
    Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, Forrest CR, Pang CY. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1435-43. doi: 10.1152/ajpheart.00106.2003. Epub 2003 Jun 5.
    Results Reference
    background
    PubMed Identifier
    15093714
    Citation
    Romano MA, Seymour EM, Berry JA, McNish RA, Bolling SF. Relative contribution of endogenous opioids to myocardial ischemic tolerance. J Surg Res. 2004 May 1;118(1):32-7. doi: 10.1016/j.jss.2003.12.006.
    Results Reference
    background
    PubMed Identifier
    14685703
    Citation
    Peart JN, Gross GJ. Exogenous activation of delta- and kappa-opioid receptors affords cardioprotection in isolated murine heart. Basic Res Cardiol. 2004 Jan;99(1):29-37. doi: 10.1007/s00395-003-0430-y. Epub 2003 Sep 29.
    Results Reference
    background
    PubMed Identifier
    11102568
    Citation
    Zhang J, Haddad GG, Xia Y. delta-, but not mu- and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury. Brain Res. 2000 Dec 8;885(2):143-53. doi: 10.1016/s0006-8993(00)02906-1.
    Results Reference
    background
    PubMed Identifier
    11997236
    Citation
    Zhang J, Gibney GT, Zhao P, Xia Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol. 2002 Jun;282(6):C1225-34. doi: 10.1152/ajpcell.00226.2001.
    Results Reference
    background
    PubMed Identifier
    10507620
    Citation
    Endoh H, Taga K, Yamakura T, Sato K, Watanabe I, Fukuda S, Shimoji K. Effects of naloxone and morphine on acute hypoxic survival in mice. Crit Care Med. 1999 Sep;27(9):1929-33. doi: 10.1097/00003246-199909000-00035.
    Results Reference
    background
    PubMed Identifier
    11373431
    Citation
    Endoh H, Honda T, Ohashi S, Shimoji K. Naloxone improves arterial blood pressure and hypoxic ventilatory depression, but not survival, of rats during acute hypoxia. Crit Care Med. 2001 Mar;29(3):623-7. doi: 10.1097/00003246-200103000-00027.
    Results Reference
    background
    PubMed Identifier
    24015136
    Citation
    Kuklin V. Survival rate in patients after sudden cardiac arrest at the university hospital of northern Norway treated with or without opioids: A retrospective evaluation. Saudi J Anaesth. 2013 Jul;7(3):310-4. doi: 10.4103/1658-354X.115355.
    Results Reference
    background
    PubMed Identifier
    25660953
    Citation
    Elmer J, Lynch MJ, Kristan J, Morgan P, Gerstel SJ, Callaway CW, Rittenberger JC; Pittsburgh Post-Cardiac Arrest Service. Recreational drug overdose-related cardiac arrests: break on through to the other side. Resuscitation. 2015 Apr;89:177-81. doi: 10.1016/j.resuscitation.2015.01.028. Epub 2015 Feb 4.
    Results Reference
    background
    PubMed Identifier
    19745156
    Citation
    Alle H, Roth A, Geiger JR. Energy-efficient action potentials in hippocampal mossy fibers. Science. 2009 Sep 11;325(5946):1405-8. doi: 10.1126/science.1174331.
    Results Reference
    background
    PubMed Identifier
    28870222
    Citation
    Xu DJ, Wang B, Zhao X, Zheng Y, Du JL, Wang YW. General anesthetics protects against cardiac arrest-induced brain injury by inhibiting calcium wave propagation in zebrafish. Mol Brain. 2017 Sep 4;10(1):44. doi: 10.1186/s13041-017-0323-x.
    Results Reference
    background
    PubMed Identifier
    2556064
    Citation
    Sterz F, Leonov Y, Safar P, Radovsky A, Stezoski SW, Reich H, Shearman GT, Greber TF. Effect of excitatory amino acid receptor blocker MK-801 on overall, neurologic, and morphologic outcome after prolonged cardiac arrest in dogs. Anesthesiology. 1989 Dec;71(6):907-18. doi: 10.1097/00000542-198912000-00014.
    Results Reference
    background
    PubMed Identifier
    8996512
    Citation
    Davis S, Helfaer MA, Traystman RJ, Hurn PD. Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs. Stroke. 1997 Jan;28(1):198-204; discussion 204-5. doi: 10.1161/01.str.28.1.198.
    Results Reference
    background
    PubMed Identifier
    15135198
    Citation
    Xiao F, Pardue S, Arnold T, Carden D, Alexander JS, Monroe J, Sharp CD, Turnage R, Conrad S. Effect of ifenprodil, a polyamine site NMDA receptor antagonist, on brain edema formation following asphyxial cardiac arrest in rats. Resuscitation. 2004 May;61(2):209-19. doi: 10.1016/j.resuscitation.2003.12.022.
    Results Reference
    background
    PubMed Identifier
    25972075
    Citation
    Bendel S, Springe D, Pereira A, Grandgirard D, Leib SL, Putzu A, Schlickeiser J, Jakob SM, Takala J, Haenggi M. Do different anesthesia regimes affect hippocampal apoptosis and neurologic deficits in a rodent cardiac arrest model? BMC Anesthesiol. 2015 Jan 15;15:2. doi: 10.1186/1471-2253-15-2.
    Results Reference
    background
    PubMed Identifier
    24973558
    Citation
    Koller AC, Salcido DD, Callaway CW, Menegazzi JJ. Resuscitation characteristics and outcomes in suspected drug overdose-related out-of-hospital cardiac arrest. Resuscitation. 2014 Oct;85(10):1375-9. doi: 10.1016/j.resuscitation.2014.05.036. Epub 2014 Jun 26.
    Results Reference
    background
    PubMed Identifier
    11310473
    Citation
    Walker A, McClelland H, Brenchley J. The Lazarus phenomenon following recreational drug use. Emerg Med J. 2001 Jan;18(1):74-5. doi: 10.1136/emj.18.1.74.
    Results Reference
    background
    Links:
    URL
    https://www.researchsquare.com/article/0895c729-0216-4dfd-9e4a-bdee2f1097d1/v1#comments
    Description
    Related Info

    Learn more about this trial

    Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival

    We'll reach out to this number within 24 hrs